Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin

progression-free survival

  • Open Access
    Atezolizumab Monotherapy for Non-small Cell Lung Cancer Patients: An Observational Study in Ibaraki Group (ATTENTION-IBARAKI)
    SHINICHIRO OKAUCHI, GEN OHARA, TOSHIHIRO SHIOZAWA, HIROKO WATANABE, TAKESHI NUMATA, RYOTA NAKAMURA, TOMOHIRO TAMURA, NORIHIRO KIKUCHI, KUNIHIKO MIYAZAKI, SHIGEN HAYASHI, HIROFUMI SAKURAI, TAKAAKI YAMASHITA, KOICHI KURISHIMA, MASAHARU INAGAKI, TAKEO ENDO, HIROICHI ISHIKAWA, TAKAYUKI KABURAGI, HIROAKI SATOH, TORU SAKAMOTO and NOBUYUKI HIZAWA
    In Vivo September 2023, 37 (5) 2203-2209; DOI: https://doi.org/10.21873/invivo.13320
  • Open Access
    Survival Outcomes With Reduced Doses of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
    JUHUN LEE, JONG MI KIM, YOON HEE LEE, GUN OH CHONG and DAE GY HONG
    In Vivo July 2022, 36 (4) 1868-1874; DOI: https://doi.org/10.21873/invivo.12905
  • Open Access
    Comparison of Survival Outcomes According to BRCA1/2 Variant Type in High-grade Serous Ovarian Cancer
    JUHUN LEE, JONG MI KIM, YOON HEE LEE, GUN OH CHONG, NAN YOUNG LEE, IN HEE LEE, JI YOUNG PARK and DAE GY HONG
    In Vivo July 2022, 36 (4) 1903-1910; DOI: https://doi.org/10.21873/invivo.12910
  • You have access
    An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer
    DAVID KISS, TANA MACHACKOVA, KAMILA SOUCKOVA, PAVEL FABIAN, IVETA KREPELKOVA, MAREK SVOBODA and IGOR KISS
    In Vivo September 2021, 35 (5) 2809-2814; DOI: https://doi.org/10.21873/invivo.12567
  • You have access
    Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma
    KAZUO KOBAYASHI, YUSUKE IIKURA, MAKOTO HIRAIDE, TAKASHI YOKOKAWA, TAKESHI AOYAMA, SARI SHIKIBU, KOKI HASHIMOTO, KENICHI SUZUKI, HITOSHI SATO, ERIKA SUGIYAMA, MASATAKA TAJIMA and TOSHIHIRO HAMA
    In Vivo September 2020, 34 (5) 2647-2652; DOI: https://doi.org/10.21873/invivo.12083
  • You have access
    Efficacy of Irinotecan as Third-line Chemotherapy for Unresectable or Recurrent Gastric Cancer
    MINORU FUKUCHI, KOHKI KUWABARA, TORU ISHIGURO, YOUICHI KUMAGAI, KEIICHIRO ISHIBASHI, ERITO MOCHIKI and HIDEYUKI ISHIDA
    In Vivo March 2020, 34 (2) 903-908; DOI: https://doi.org/10.21873/invivo.11856
  • You have access
    Retrospective Analysis of Trabectedin Therapy for Soft Tissue Sarcoma
    KUNIKI KAWAGUCHI, KENJI NAKANO, TETSUYA URASAKI, NAOKI FUKUDA, SHINICHIRO TAIRA, MAKIKO ONO, JUNICHI TOMOMATSU, MASATOSHI NISHIZAWA, KEISUKE AE, SEIICHI MATSUMOTO and SHUNJI TAKAHASHI
    In Vivo September 2019, 33 (5) 1609-1614; DOI: https://doi.org/10.21873/invivo.11644
In Vivo

© 2023 In Vivo

Powered by HighWire